about
Correlation between SD-OCT, immunocytochemistry and functional findings in an animal model of retinal degeneration.Retinal degeneration in two lines of transgenic S334ter ratsThe influence of the polar head-group of synthetic cationic lipids on the transfection efficiency mediated by niosomes in rat retina and brain.Protamine/DNA/Niosome Ternary Nonviral Vectors for Gene Delivery to the Retina: The Role of Protamine.Enduring high-efficiency in vivo transfection of neurons with non-viral magnetoparticles in the rat visual cortex for optogenetic applications.A novel cationic niosome formulation for gene delivery to the retina.Retinal gene delivery enhancement by lycopene incorporation into cationic niosomes based on DOTMA and polysorbate 60.Niosomes based on synthetic cationic lipids for gene delivery: the influence of polar head-groups on the transfection efficiency in HEK-293, ARPE-19 and MSC-D1 cells.Gradual morphogenesis of retinal neurons in the peripheral retinal margin of adult monkeys and humans.Functional and structural modifications during retinal degeneration in the rd10 mouse.Morphological impairments in retinal neurons of the scotopic visual pathway in a monkey model of Parkinson's disease.The S1P1 receptor-selective agonist CYM-5442 protects retinal ganglion cells in endothelin-1 induced retinal ganglion cell loss.Transcranial direct-current stimulation (tDCS) improves detection of simple bright stimuli by amblyopic Long Evans rats in the SLAG task and produces an increase of parvoalbumin labelled cells in visual corticesPolysorbate 20 non-ionic surfactant enhances retinal gene delivery efficiency of cationic niosomes after intravitreal and subretinal administrationGene transfer to rat cerebral cortex mediated by polysorbate 80 and poloxamer 188 nonionic surfactant vesiclesNon-viral vectors based on cationic niosomes as efficient gene delivery vehicles to central nervous system cells into the brainNon-viral vectors based on cationic niosomes and minicircle DNA technology enhance gene delivery efficiency for biomedical applications in retinal disorders
P50
Q34755346-1E52DF59-279D-460E-BB8C-8D8BA596F958Q34777839-CEB46650-0E55-405A-AB2C-A88AC5035721Q38816429-178082FA-F3AD-4831-A4BE-11D5C982354DQ38838421-F24D93FB-7AA2-4336-A2B6-84BFC3B3F7CAQ39039124-C569BFF5-7E22-4E6A-9FEA-22313F52A063Q39063156-8D2210E5-19AC-4ADA-A51A-B5051F8D38A1Q40271537-57D99B0A-92CA-4D36-91D5-26757249ECA3Q42181014-98FACD8B-BD35-4966-9758-65ABDD6C0BB5Q46328368-24200E23-7F07-4DD3-9FB6-7284D6E39FE3Q46474597-CDCC0E70-299E-4F6B-82B7-58604B4520C8Q46778830-55CB8E40-B4D0-42F0-A7C0-C6D7448AA5B0Q47732307-59E3715F-0980-45CB-97DE-A23E6E18EC76Q57053004-9828BEBA-537B-43B7-AAC8-3F3DF3381E27Q57785860-23676E51-8C0D-4BDF-8C00-AE675D3A3DAEQ59797976-2AC7177B-A8FE-4663-8D14-AC5DB1BEF4D7Q91655256-BFFB9DF6-6E1B-4AB4-855C-7037C7D1E7D4Q91801634-300C5302-45B7-47A8-808E-CDF163ED0AC1
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Gema C Martínez-Navarrete
@en
Gema C Martínez-Navarrete
@nl
type
label
Gema C Martínez-Navarrete
@en
Gema C Martínez-Navarrete
@nl
prefLabel
Gema C Martínez-Navarrete
@en
Gema C Martínez-Navarrete
@nl
P31
P496
0000-0002-9795-2846